Osiris Therapeutics, Inc.  

(Public, NASDAQ:OSIR)   Watch this stock  
Find more results for OSIR
+0.08 (1.43%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.49 - 5.75
52 week 3.55 - 23.67
Open 5.63
Vol / Avg. 74,051.00/129,069.00
Mkt cap 198.14M
P/E 115.10
Div/yield 0.20
EPS 0.05
Shares 34.45M
Beta 0.76
Inst. own 37%
Jun 9, 2016
Osiris Therapeutics Inc Annual Shareholders Meeting (Estimated) - 1:30PM EDT - Add to calendar
Apr 7, 2016
Q4 2015 Osiris Therapeutics Inc Earnings Release (Estimated)
Mar 22, 2016
Osiris Therapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Investor Day
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -2.60% -0.41%
Operating margin 1.22% 2.87%
EBITD margin - 4.44%
Return on average assets -2.59% -0.26%
Return on average equity -3.13% -0.30%
Employees 211 -
CDP Score - -


7015 Albert Einstein Drive
United States - Map
+1-443-5451800 (Phone)
+1-443-5451701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Osiris Therapeutics, Inc. is a medical products company. The Company is focused on developing and marketing products in regenerative medicine, including bioengineering, stem cell research and viable tissue based products. The Company's offers products in orthopedics, sports medicine and wound care, including Cartiform, BIO4 and Grafix. Cartiform is a viable chondral allograft containing viable chondrocytes, chondrogenic growth factors, and extracellular matrix proteins within the intact architecture of healthy hyaline cartilage. BIO4 is a bone allograft that contains both viable cells and growth factors. It is a safe alternative to autograft that minimizes the potential for harvest site co-morbidities. Grafix is a cryopreserved placental membrane that preserves the native properties and inherent functionality of the tissue.

Officers and directors

Peter Friedli Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Dwayne Montgomery President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Gregory I. Law Chief Financial Officer, Corporate Secretary and Treasurer
Age: 48
Bio & Compensation  - Reuters
Frank D. Czworka Jr. Vice President, General Manager of Wound Care
Age: 46
Bio & Compensation  - Reuters
Adrian P. Mollo General Counsel
Age: 40
Bio & Compensation  - Reuters
Alla N. Danilkovitch Ph.D. Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Thomas M. Brandt Jr. Independent Director
Age: 63
Bio & Compensation  - Reuters
Hans-Georg Klingemann M.D., Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Jay M. Moyes Independent Director
Age: 61
Bio & Compensation  - Reuters